Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

[1]  Jiayan Huang,et al.  VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). , 2014, JAMA ophthalmology.

[2]  Christian Simader,et al.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.

[3]  G. Ying,et al.  Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group‡* , 2012 .

[4]  G. Ying,et al.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.

[5]  W. Freeman,et al.  HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. , 2012, Ophthalmology.

[6]  G. Yancopoulos,et al.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.

[7]  P. Rosenfeld,et al.  PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE) , 2011, Retina.

[8]  N. Bressler,et al.  Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. , 2011, Archives of ophthalmology.

[9]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[10]  U. Schmidt-Erfurth,et al.  Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. , 2011, Ophthalmology.

[11]  C. Regillo,et al.  A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. , 2010, Ophthalmology.

[12]  K. Freund,et al.  LONG-TERM FOLLOW-UP FOR TYPE 1 (SUBRETINAL PIGMENT EPITHELIUM) NEOVASCULARIZATION USING A MODIFIED “TREAT AND EXTEND” DOSING REGIMEN OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY , 2010, Retina.

[13]  Sumit Sharma,et al.  Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. , 2009, Ophthalmology.

[14]  G. Quentel,et al.  Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. , 2009, American journal of ophthalmology.

[15]  C. Regillo,et al.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. , 2008, American journal of ophthalmology.

[16]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[17]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[18]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[19]  R. Klein,et al.  Causes and prevalence of visual impairment among adults in the United States. , 2004, Archives of ophthalmology.

[20]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Philip J Rosenfeld,et al.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.

[22]  Peter K. Kaiser,et al.  ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .